查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010934

甲狀腺癌治療市場：按癌症類型、治療方法、藥物類型、給藥途徑和最終用戶分類－2026年至2032年全球市場預測

Thyroid Cancer Drugs Market by Cancer Type, Treatment Modality, Drug Type, Mode Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，甲狀腺癌治療市場價值將達到 9.9483 億美元，到 2026 年將成長至 10.9292 億美元，到 2032 年將達到 21.1444 億美元，複合年成長率為 11.37%。

主要市場統計數據
基準年 2025 9.9483億美元
預計年份：2026年 1,092,920,000 美元
預測年份 2032 211444億美元
複合年成長率 (%) 11.37%

為策略決策者提供關於重塑甲狀腺癌治療格局的臨床、商業性和營運促進因素的全面概述。

甲狀腺癌的治療模式正在迅速發展，無論從科學層面或臨床層面來看，新的治療方法都在重塑臨床路徑和相關人員的預期。本執行摘要旨在為讀者概述當前治療方法、產品類型和終端用戶趨勢，並闡述其對製藥公司、保險公司、醫療服務提供者和臨床研究人員的戰略意義。

先進的診斷技術、監管柔軟性和門診護理趨勢如何匯聚起來，改變甲狀腺癌治療的模式以及相關人員的角色？

過去幾年，甲狀腺癌的治療模式已從相對靜態的治療模式轉變為以動態創新和治療方法多樣化為特徵的模式。精準診斷和分子分層提高了標靶治療的重要性，使臨床醫生能夠根據腫瘤突變譜和抗藥性模式製定個人化的治療方法。因此，多激酶抑制劑和選擇性標靶藥物的臨床應用範圍不斷擴大，而免疫療法聯合治療在治療困難組織學亞型方面也得到了越來越多的探索。

評估 2025 年關稅對供應鏈調整的影響及其對甲狀腺癌治療的採購、臨床運作和取得策略的下游影響。

2025年關稅和貿易政策調整的實施，為全球醫藥供應鏈引入了新的變數，並帶來了可衡量的營運和策略影響。對於甲狀腺癌治療而言，由於其通常依賴複雜活性成分的採購和跨境生產，進口關稅的提高進一步凸顯了供應鏈透明度和雙重採購策略的重要性。累積而言，採購慣例已被重新評估，重點也再次轉向最佳化製造地，以降低關稅變化帶來的風險。

將癌症組織學類型、治療方法、藥物類別、給藥途徑和最終用戶趨勢與商業化和臨床策略要求聯繫起來的詳細細分分析。

基於細分市場的洞察揭示了有助於產品開發、市場進入規劃和臨床定位的細微模式。本分析基於癌症類型，涵蓋了未分化型甲狀腺癌 (ATC)、濾泡型甲狀腺癌 (FTC)、哈特爾細胞癌、髓樣甲狀腺癌 (MTC) 和乳頭狀甲狀腺癌 (PTC)，重點闡述了它們各自獨特的自然病程和治療需求，這些差異決定了臨床優先事項和循證策略的不同。按治療方法分類，本研究檢驗了化療、免疫療法、放射性碘療法、手術、靶向多激酶療法和甲狀腺刺激素(TSH) 抑制療法，展示了每種治療方法的獨特價值提案如何影響治療方法選擇、報銷途徑和跨學科合作。

美洲、歐洲、中東和非洲以及亞太地區的臨床、監管和進入趨勢影響招募和打入市場策略。

區域情報重點在於影響全球市場治療策略的區域性監管、臨床和准入趨勢。在美洲，法規環境強調快速核准途徑和可靠的真實世界證據收集，從而支持加速採用生物標記主導治療方法，並為基於療效和管理式准入合約創造機會。該地區的臨床實踐正日益整合多學科診療模式和先進的基因組檢測，推動精準醫療和口服治療方法的早期應用。

決定甲狀腺腫瘤學成功與否的競爭和企業策略，包括產品線優先排序、診斷領域的合作以及以結果主導的商業化能力。

企業層面的發展趨勢對甲狀腺腫瘤領域的競爭定位和治療方法差異化至關重要。領先的製藥和生技公司正透過內部藥物研發、策略聯盟和有針對性的收購等多種方式推進其研發管線，尤其關注針對侵襲性或難治性組織學類型甲狀腺腫瘤的未滿足醫療需求的藥物。縱觀整體競爭格局，成功的公司往往能夠將強大的臨床項目與清晰的伴隨診斷策略以及上市後核准實踐計劃相結合。

為製藥公司和支付方提供切實可行的建議，以協調診斷、供應彈性、患者支持和靈活契約，從而實現持續的治療成功。

行業領導者應採取一系列有針對性的行動，將科學進步轉化為永續的患者獲益。應優先將分子診斷儘早整合到臨床開發計劃中，並透過使研究終點與支付方關注的結果一致，簡化報銷談判流程。同時，應投資於供應鏈冗餘和近岸生產方案，以減輕關稅和貿易相關干擾，並確保及時獲得關鍵治療方法。

結合專家訪談、第二手資料審查和檢驗技術的穩健混合方法研究框架，確保了可操作和可靠的見解。

本分析的研究方法結合了結構化的原始研究和全面的二手研究，並輔以嚴格的檢驗。原始資料來自對臨床專業人員、相關專科的資深臨床醫生、供應鏈負責人和支付方的深入訪談，旨在了解第一線人員對治療模式、獲取障礙和實際情況的觀點。二手研究則整合了同儕審查的文獻、監管文件、臨床試驗註冊資訊和公開的產品標籤，以闡明治療機制和證據成熟度。

將臨床、商業性和營運方面的挑戰進行策略整合，相關人員必須解決這些挑戰，才能將創新與改善患者預後連結起來。

總之，甲狀腺癌治療領域正朝著更個人化、主導的模式轉變，診斷、治療和醫療服務緊密結合。精準醫學的進步和新的監管途徑正在加速臨床應用，但同時也需要完善的商業化和運作策略，以確保患者獲得治療並維持臨床效益。此外，關稅和區域政策差異等外部因素帶來的供應鏈風險，凸顯了適應性規劃和合作夥伴關係的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按癌症類型分類的甲狀腺癌治療市場

  • 未分化型甲狀腺癌（ATC）
  • 濾泡性甲狀腺癌（FTC）
  • 哈斯勒細胞癌
  • 甲狀腺髓樣癌（MTC）
  • 乳突狀甲狀腺癌（PTC）

第9章：甲狀腺癌治療市場（依治療方法分類）

  • 化療
  • 免疫療法
  • 放射性碘療法
  • 外科手術
  • 標靶多激酶療法
  • 甲狀腺刺激素（TSH）抑制療法

第10章：甲狀腺癌治療藥物市場

  • 化療藥物
  • 荷爾蒙療法藥物
  • 免疫療法藥物
  • 分子標靶療法

第11章：按給藥途徑分類的甲狀腺癌治療藥物市場

  • 注射藥物
    • 預填充式注射器
    • 管瓶
  • 口服
    • 膠囊
    • 藥片

第12章 甲狀腺癌治療市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 腫瘤診所
  • 研究機構

第13章 甲狀腺癌治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 甲狀腺癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 甲狀腺癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國甲狀腺癌治療市場

第17章：中國甲狀腺癌治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • Cellectar Biosciences, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Genentech, Inc
  • Ipsen SA
  • Janssen Pharmaceuticals, Inc.
  • Loxo Oncology, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-434CCDA052BE

The Thyroid Cancer Drugs Market was valued at USD 994.83 million in 2025 and is projected to grow to USD 1,092.92 million in 2026, with a CAGR of 11.37%, reaching USD 2,114.44 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 994.83 million
Estimated Year [2026] USD 1,092.92 million
Forecast Year [2032] USD 2,114.44 million
CAGR (%) 11.37%

Comprehensive overview of clinical, commercial, and operational drivers reshaping the thyroid cancer treatment landscape for strategic decision-makers

The therapeutic landscape for thyroid cancer is undergoing rapid scientific and clinical evolution, with novel modalities reshaping clinical pathways and stakeholder expectations. This executive summary sets out to orient readers to the current state of play across treatment approaches, product classes, and end-user dynamics, and to outline strategic implications for manufacturers, payers, providers, and clinical researchers.

Beginning with a concise framing of disease heterogeneity and clinical urgency, the narrative moves through the contemporary therapeutic mix and the forces driving change, including regulatory approvals, real-world evidence generation, and shifts in care delivery. Emphasis is given to the interplay between targeted molecular therapies, immuno-oncology agents, and established modalities such as surgery and radioiodine, underscoring how multidisciplinary treatment decisions now rely on increasingly precise biomarker and genomic information.

Importantly, the introduction also highlights commercial and operational considerations that accompany scientific progress - from supply chain resilience to patient access pathways - setting the context for the deeper analytical sections that follow. This establishes the foundation for informed strategic planning and investment prioritization in thyroid cancer therapeutics.

How precision diagnostics, regulatory flexibility, and outpatient care trends are converging to transform thyroid cancer treatment paradigms and stakeholder roles

Across the past several years, the thyroid cancer landscape has shifted from a relatively static treatment paradigm to one characterized by dynamic innovation and therapeutic diversification. Precision diagnostics and molecular stratification have elevated the importance of targeted therapies, enabling clinicians to tailor treatment regimens to tumor mutation profiles and resistance patterns. Consequently, the clinical role of multikinase inhibitors and selective targeted agents has expanded, while immunotherapy combinations are increasingly explored for difficult-to-treat histologies.

Parallel to scientific advances, regulatory frameworks have adapted to accommodate accelerated approval pathways, conditional authorizations, and label expansions driven by biomarker-defined cohorts. Health systems are responding to these changes by investing in multidisciplinary tumor boards and genomic testing infrastructure, which in turn influence referral patterns and treatment sequencing. Additionally, the maturation of oral onco-pharmaceuticals and outpatient-centered regimens is shifting care away from inpatient settings, with implications for administration, adherence, and long-term patient management.

In short, transformative shifts are being driven by a convergence of precision medicine, regulatory flexibility, and care-delivery realignment, creating both opportunities for innovative therapeutics and operational challenges for manufacturers and providers alike.

Assessment of 2025 tariff-driven supply chain recalibrations and their downstream effects on procurement, clinical operations, and access strategies for thyroid cancer therapies

The imposition of tariffs and trade policy adjustments in 2025 introduced new variables into the global pharmaceutical supply chain with measurable operational and strategic consequences. For thyroid cancer therapeutics, which often rely on complex active pharmaceutical ingredient sourcing and cross-border manufacturing, increased import duties have amplified the importance of supply chain mapping and dual-sourcing strategies. The cumulative effect has been a re-evaluation of procurement practices and a renewed focus on manufacturing footprint optimization to mitigate exposure to tariff volatility.

Moreover, tariffs have reinforced the need for greater transparency in costing and pricing strategy. Organizations are increasingly factoring potential trade-related cost pressures into procurement contracts and long-term supplier partnerships. Clinical trial logistics have also been impacted, with sponsors adjusting trial site selection and investigational medicinal product distribution plans to reduce customs-related delays and ensure continuity of patient access to investigational therapies.

Finally, in response to these headwinds, stakeholders have accelerated investments in near-shore manufacturing, supply resiliency programs, and collaborative contracting models. These adaptations aim to preserve therapeutic availability and protect patient access while maintaining predictable delivery timelines in a changing tariff environment.

Deep segmentation analysis linking cancer histology, treatment modality, drug class, administration route, and end-user dynamics to commercialization and clinical strategy imperatives

Segmentation-based insights reveal nuanced patterns that inform product development, market access planning, and clinical positioning. Based on Cancer Type, the analysis covers Anaplastic Thyroid Cancer (ATC), Follicular Thyroid Cancer (FTC), Hurthle Cell Carcinoma, Medullary Thyroid Cancer (MTC), and Papillary Thyroid Cancer (PTC), highlighting the distinct natural histories and therapeutic needs that dictate differential clinical priorities and evidence generation strategies. Based on Treatment Modality, the study examines Chemotherapy, Immunotherapy, Radioiodine Therapy, Surgery, Targeted Multikinase Therapy, and Thyroid Stimulating Hormone (TSH) Suppression Therapy, demonstrating how modality-specific value propositions influence adoption, reimbursement pathways, and cross-specialty coordination.

Based on Drug Type, distinctions among Chemotherapy Agents, Hormone Therapy Drugs, Immunotherapy Drugs, and Targeted Therapy Drugs underscore the varying development timelines, safety profiles, and companion diagnostic dependencies that sponsors must navigate. Based on Mode Of Administration, injectable and oral forms are evaluated, with the Injectable further disaggregated into Pre-Filled Syringes and Vials and the Oral subdivided into Capsules and Tablets; this distinction influences manufacturing complexity, patient adherence patterns, and distribution logistics. Based on End User, the report addresses Homecare Settings, Hospitals, Oncology Clinics, and Research Organizations, each representing unique purchasing behaviors, clinical workflows, and post-market evidence opportunities.

Taken together, these segmentation lenses demonstrate that effective commercialization strategies require an integrated approach that aligns clinical development with administration logistics and end-user dynamics, while also prioritizing evidence generation that resonates with the decision criteria of diverse stakeholder groups.

Region-specific clinical, regulatory, and access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption and market entry strategies

Regional intelligence highlights distinct regulatory, clinical, and access dynamics that shape therapeutic strategy across global markets. In the Americas, the regulatory environment emphasizes expedited review pathways and robust real-world evidence collection, which supports accelerated uptake for biomarker-driven therapies and creates opportunities for outcome-based contracting and managed entry agreements. Clinical practice in this region tends to integrate multidisciplinary care delivery models and advanced genomic testing, driving early adoption of precision therapeutics and oral treatment regimens.

In Europe, Middle East & Africa, fragmentation across regulatory frameworks and reimbursement systems necessitates tailored market entry tactics that account for country-level HTA processes, variability in diagnostic infrastructure, and differences in hospital procurement. Stakeholders should prioritize evidence packages that align with regional HTA endpoints and invest in local clinician engagement to navigate heterogeneous payer environments. Additionally, capacity constraints in parts of the region can influence access to advanced modalities such as radioiodine therapy and immuno-oncology combinations.

In Asia-Pacific, diverse regulatory timelines and accelerating investment in oncology research create a complex but opportunity-rich landscape. Many jurisdictions in this region are expanding molecular testing and decentralizing cancer care, which in turn supports broader population access to targeted and oral therapies. Strategic partnerships with local manufacturers, attention to pricing and reimbursement nuances, and investment in regional real-world evidence generation will be critical to achieving sustainable access and uptake across Asia-Pacific markets.

Competitive and corporate strategies that define success in thyroid oncology including pipeline prioritization, diagnostics partnerships, and outcome-driven commercialization capabilities

Company-level dynamics are central to competitive positioning and therapeutic differentiation in thyroid oncology. Leading pharmaceutical and biotechnology companies are advancing pipelines through a combination of internal discovery, strategic collaborations, and targeted acquisitions, with particular emphasis on agents that address unmet needs in aggressive or refractory histologies. Across the competitive set, successful companies are those that couple robust clinical programs with clear companion diagnostic strategies and post-authorization evidence generation plans.

Commercially, organizations that invest in integrated launch capabilities - combining payer engagement, clinician education, and patient support services - are better positioned to accelerate uptake of new therapies. Operational excellence in supply chain management and manufacturing scale-up is equally critical to avoid launch disruptions and to support global demand. Partnerships between biopharma firms and diagnostic providers are increasingly common, reflecting the need to bundle testing and treatment pathways to optimize clinical outcomes and payer value assessments.

Finally, companies demonstrating agility in pricing models and contracting arrangements, including risk-sharing agreements and value-based frameworks, are more likely to secure access in environments where payers demand demonstrable outcomes. These company-level approaches collectively define who will convert clinical innovation into sustained therapeutic impact.

Practical and high-impact recommendations for manufacturers and payers to align diagnostics, supply resilience, patient support, and flexible contracting for sustained therapeutic success

Industry leaders should adopt a set of targeted actions to translate scientific progress into sustainable patient impact. Prioritize integration of molecular diagnostics into clinical development plans early, aligning study endpoints with payer-relevant outcomes to streamline reimbursement discussions. Simultaneously, invest in supply chain redundancies and near-shore manufacturing options to mitigate tariff and trade-related disruptions while preserving timely access to critical therapies.

Moreover, foster collaborations across the ecosystem by forming partnerships with diagnostic companies, academic centers, and regional distributors to expedite adoption and to build localized evidence. Enhance patient support programs to address adherence and administration barriers, particularly as oral regimens and homecare delivery models become more prevalent. From a commercial perspective, develop flexible contracting strategies that allow for outcome-based elements and adaptive pricing aligned with real-world performance.

Finally, embed agile decision-making processes into R&D and commercial operations so that learnings from early real-world deployments can rapidly inform label expansions, combination therapy studies, and lifecycle management. These actions will help organizations convert innovation into measurable clinical and commercial success.

Robust mixed-methods research framework combining expert interviews, secondary evidence review, and validation techniques to ensure actionable and credible insights

The research approach underpinning this analysis combines structured primary research with comprehensive secondary synthesis and rigorous validation. Primary inputs were derived from in-depth interviews with clinical experts, senior clinicians across relevant specialties, supply chain leaders, and payers to capture first-hand perspectives on treatment patterns, access hurdles, and operational realities. Secondary synthesis incorporated peer-reviewed literature, regulatory documentation, clinical trial registries, and publicly available product labels to contextualize therapeutic mechanisms and evidence maturations.

Data validation involved triangulating stakeholder interviews with clinical guideline trends and regulatory actions to ensure consistency and to identify divergences between trial settings and real-world practice. The methodology also employed scenario analysis to stress-test assumptions around supply disruptions, policy shifts, and treatment pathway changes. Where applicable, patient pathway mapping was used to surface friction points in diagnosis, treatment initiation, and long-term follow-up.

Collectively, these methodological elements ensure that the insights presented are grounded in real-world clinical practice and operational feasibility, providing a robust foundation for strategic decision-making by industry and clinical stakeholders.

Strategic synthesis of clinical, commercial, and operational imperatives that stakeholders must address to convert innovation into improved patient outcomes

In conclusion, the thyroid cancer therapeutic arena is transitioning toward a more personalized, evidence-driven paradigm in which diagnostics, therapeutics, and care delivery are tightly interdependent. Precision medicine advances and new regulatory pathways are enabling faster clinical translation, but they also demand sophisticated commercialization and operational strategies to ensure patient access and to sustain clinical benefit. Moreover, external dynamics such as tariff-induced supply chain risks and regional policy heterogeneity underscore the importance of adaptive planning and collaborative partnerships.

For stakeholders seeking to lead in this environment, success will hinge on aligning clinical development with payer-relevant evidence, building resilient manufacturing and distribution networks, and investing in end-user engagement across hospitals, clinics, and homecare settings. By doing so, manufacturers, providers, and policymakers can collectively improve outcomes for diverse thyroid cancer patient populations while navigating the complex commercial and operational landscape.

This summary provides a strategic vantage point for executives and clinicians to prioritize initiatives that will have the greatest impact on patient care and organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Thyroid Cancer Drugs Market, by Cancer Type

  • 8.1. Anaplastic Thyroid Cancer (ATC)
  • 8.2. Follicular Thyroid Cancer (FTC)
  • 8.3. Hurthle Cell Carcinoma
  • 8.4. Medullary Thyroid Cancer (MTC)
  • 8.5. Papillary Thyroid Cancer (PTC)

9. Thyroid Cancer Drugs Market, by Treatment Modality

  • 9.1. Chemotherapy
  • 9.2. Immunotherapy
  • 9.3. Radioiodine Therapy
  • 9.4. Surgery
  • 9.5. Targeted Multikinase Therapy
  • 9.6. Thyroid Stimulating Hormone (TSH) Suppression Therapy

10. Thyroid Cancer Drugs Market, by Drug Type

  • 10.1. Chemotherapy Agents
  • 10.2. Hormone Therapy Drugs
  • 10.3. Immunotherapy Drugs
  • 10.4. Targeted Therapy Drugs

11. Thyroid Cancer Drugs Market, by Mode Of Administration

  • 11.1. Injectable
    • 11.1.1. Pre-Filled Syringes
    • 11.1.2. Vials
  • 11.2. Oral
    • 11.2.1. Capsules
    • 11.2.2. Tablets

12. Thyroid Cancer Drugs Market, by End User

  • 12.1. Homecare Settings
  • 12.2. Hospitals
  • 12.3. Oncology Clinics
  • 12.4. Research Organizations

13. Thyroid Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Thyroid Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Thyroid Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Thyroid Cancer Drugs Market

17. China Thyroid Cancer Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. Blueprint Medicines Corporation
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Cellectar Biosciences, Inc.
  • 18.12. Eisai Co., Ltd.
  • 18.13. Eli Lilly and Company
  • 18.14. Exelixis, Inc.
  • 18.15. Genentech, Inc
  • 18.16. Ipsen SA
  • 18.17. Janssen Pharmaceuticals, Inc.
  • 18.18. Loxo Oncology, Inc.
  • 18.19. Merck & Co., Inc.
  • 18.20. Novartis AG
  • 18.21. Pfizer Inc.
  • 18.22. Roche Holding AG
  • 18.23. Sanofi S.A.
  • 18.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. G7 THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 197. NATO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)